Novotech Honored with Triple Win in 2025 Pharmaceutical Technology Excellence Awards
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies, is proud to announce its recognition across three categories—Diversity, Research and Development, and Marketing— as part of the Categories - Pharmaceutical Technology, one of the industry’s most prestigious and widely recognized independent recognition programs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521133918/en/

Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory partner, is proud to announce its recognition across three categories—Diversity, Research and Development, and Marketing— as part of the Pharmaceutical Technology Awards by Global Data, one of the industry’s most prestigious and widely recognized independent recognition programs.
Powered by GlobalData’s business intelligence, the Pharmaceutical Technology Excellence Awards analyze over one billion datasets annually to identify and celebrate forward-thinking, innovative companies driving positive change in the pharmaceutical sector. The program recognizes excellence across 12 key areas including Diversity, Research and Development, and Marketing.
Diversity Leadership
Novotech received the Diversity award for its outstanding commitment to advancing gender representation and leadership within its global workforce. With women comprising 74% of its global workforce and 40% of senior leadership roles, Novotech significantly exceeds industry benchmarks. The company’s multifaceted approach includes inclusive hiring practices, unconscious bias training, pay equity initiatives, and robust employee resource groups, fostering a culture where diversity is actively promoted and women are empowered to thrive at all levels.
"We are honored and proud to receive the Diversity – Women Leadership Award. This recognition is especially meaningful because it reflects a core part of our identity: fostering a workplace where women are supported to lead, grow, and thrive with confidence. Our strong representation of female employees is a key aspect of what makes Novotech unique, and with women comprising 74% of our workforce and 40% of Executive leadership roles, we are proud to exceed industry benchmarks and champion female leadership at every level. This award affirms our belief that diverse leadership is not only essential to equity — it’s a driving force behind innovation, excellence, and real impact in clinical research.” — Angela Edwardson, Chief People Officer, Novotech
Pioneering Research and Development
Novotech was recognized in the Research and Development category for its innovative partnership with Tune Therapeutics, a leader in epigenome editing. Together, the organizations are conducting a first-in-human, multicenter clinical study of Tune-401, a first-in-class epigenetic silencing therapy for Chronic Hepatitis B. This collaboration marks a significant milestone as the first application of epigenome editing technology to target a common infectious disease, leveraging Novotech’s regulatory expertise and extensive clinical network to reach patient populations most affected by Hepatitis B.
“This recognition reflects Novotech’s commitment to a true partnership approach—working alongside biotech and small to mid-size pharma companies as an extension of their team. By combining scientific expertise with regional insight and operational focus, we support each client’s development goals with flexibility and precision. We’re proud to play a role in advancing innovative therapies through trusted, collaborative relationships. — Dr. John Moller, Chief Executive Officer, Novotech
Innovative Marketing Initiatives
Novotech also received the Marketing award for its targeted ridesharing advertisement campaign during the 2025 JP Morgan Annual Conference in San Francisco. By leveraging in-app advertising on ridesharing platforms, Novotech delivered tailored messages to biotech and pharmaceutical professionals, achieving strong engagement and brand visibility. The campaign’s innovative use of geo-targeting and real-time calls-to-action resulted in over 72,000 trips, more than 1,650 clicks, and a click-through rate surpassing industry benchmarks.
“This recognition speaks to the strength of our strategy in using targeted, innovative channels to engage the biotech and pharma community in ways that are relevant, timely, and meaningful. It’s a reflection of how we continue to adapt our approach to meet the expectations of a rapidly evolving market." – Toyna Chin, Global Director of Marketing, Novotech
About the Pharmaceutical Technology Excellence Awards
The Pharmaceutical Technology Excellence Awards, powered by GlobalData, is one of the largest and most respected recognition programs in the industry, analyzing data from over 200 countries to identify and endorse companies leading the way in 12 key Areas of Excellence. Novotech won in three of the 12 Areas of Excellence.
About NovotechNovotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company providing biotech and small- to mid-sized pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations.
Novotech leverages its therapeutic and regulatory expertise, client-centric service model, local market insights, and advanced analytical tools to expedite patient recruitment, enhance trial efficiencies, and bring life-changing therapies to market faster. This work has been recognized by awards such as the Frost & Sullivan CRO Company of the Year, which Novotech has received for 19 consecutive years.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250521133918/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curatis discloses Corticorelin as active substance of C-PTBE-0123.5.2025 07:00:00 CEST | Press release
Corticorelin Market Opportunity in Peritumoral Brain Edema (PTBE) expected to exceed USD 1 billion; Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog An epidemiological market study commissioned by Curatis Holding AG (SIX:CURN, “Curatis”) shows that the target patient group is substantially larger than previous estimates. In the US alone, over 150,000 patients suffer from peritumoral brain edema in association with malignant tumors. In previous clinical studies, human corticorelin (C-PTBE-01), demonstrated significant benefits in the treatment of PTBE. “The prospect of developing a potential blockbuster drug with that can contribute significantly to the quality of life of many patients, combined with the potential of maintaining the efficacy of immunotherapies for these patients, is very motivating and exciting,” said Dr. Roland Rutschmann, Curatis CEO. Key statements Corticorelin (hCRH), a 41 amino acid endogenous polypeptide, has demonstrated the ability to positively imp
Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 202522.5.2025 23:43:00 CEST | Press release
Data from Phase 3 MANEUVER study demonstrating significant improvements in physical function and symptoms in patients with tenosynovial giant cell tumor (TGCT) treated with pimicotinib, to be featured in oral presentationLatest results for potential first-in-class anti-CEACAM5 ADC precemtabart tocentecan (M9140) highlight strong rationale for further development in colorectal cancer (CRC)Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago. The presentations include the Phase 3 MANEUVER data for potentially best-in-class pimicotinib in the treatment of the rare tumor TGCT, as well as data from both company- and investigator-sponsored studies highlighting the company’s focus on advancing differentiated molecules to tackle some of the most challenging cancers.
Cooperation between Topcon Positioning Systems and Amberg Technologies Ltd.22.5.2025 22:17:00 CEST | Press release
Topcon Positioning Systems and Amberg Technologies Ltd. have initiated a close collaboration to enable interoperability between Topcon’s sensor solutions and Amberg Technologies’ software and hardware platforms for rail and tunnel applications. This marks the first step towards offering fully integrated solutions to our shared customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522363239/en/ Luc Le Maire, Senior Vice President, Topcon (left) and Johannes Mueller, CEO, Amberg Technologies. About Topcon Positioning Systems Topcon Positioning Systems is an industry-leading designer, manufacturer and distributor of precision measurement and workflow solutions for the global construction, geospatial and agriculture markets. Topcon Positioning Systems is headquartered in Livermore, California, U.S. (topconpositioning.com, LinkedIn, X, Facebook, Instagram). Its European head office is in Zoetermeer, Netherlands. Topcon Cor
LBT Holdings Ltd. Acquires Gonet Bank & Trust Limited, Introducing Bank of Nassau to Uphold the Finest Traditions of Private Banking22.5.2025 18:29:00 CEST | Press release
LBT Holdings Ltd., in partnership with Gonet SA, is pleased to announce the successful acquisition of Gonet Bank & Trust Limited, a distinguished Bahamas-based private bank formerly owned by Gonet SA. The transaction, which has received full regulatory approval from the Swiss Financial Market Supervisory Authority (FINMA), the Central Bank of The Bahamas (CBOB), and The Securities Commission of The Bahamas (SCB), marks a significant milestone for both organizations. Effective immediately, LBT Holdings Ltd. assumes 100% ownership of Gonet Bank & Trust Limited. As part of this strategic transition, Gonet Bank & Trust Limited will be rebranded as Bank of Nassau 1982 Limited, reflecting its renewed vision and commitment to excellence in private banking and wealth management. This acquisition strengthens the position of all parties in the global financial services sector, enabling expanded service offerings while upholding the highest standards of client-centric banking. Bank of Nassau 1982
Andersen Global indvier medlemsfirmaer i Usbekistan og styrker sin tilstedeværelse i Centralasien22.5.2025 16:34:00 CEST | Pressemeddelelse
Andersen Global styrker sin tilstedeværelse i Centralasien med tilføjelsen af Andersen i Usbekistan, hvilket er en del af den fortsatte udvidelse af organisationens kapaciteter i regionen. Firmaet blev grundlagt i 2009 under navnet Virtus Leo og ledes af den administrerende partner Alisher Zaynutdinov. Siden 2021 har det været samarbejdspartner med Andersen Global. Teamet tilbyder tjenester inden for skatte- og juraforhold inden for en bred vifte af sektorer, herunder overholdelse af skattelovgivningen for selskabser og enkeltpersoner, rådgivning om direkte og indirekte skat, transferpriser, ledelsesrapportering og -analyse, selskabsledelse, konkurrenceret og antitrust, selskabs- og bankret, arbejds- og ansættelsesret, retssager og undersøgelser, fusioner og opkøb, fast ejendom, energi, immaterialret samt familieret. "I kraft af vores professionalisme, gennemsigtighed og evne til at se løsninger samt analytiske tilgang til alle opgaver er vi godt positioneret til at rådgive vores klien
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom